论文部分内容阅读
目的:探讨尿核基质蛋白22(NMP22)联合尿脱落细胞学检测对膀胱移行细胞癌诊断及术后复发监测中的应用价值。方法:采用酶联免疫法(ELISA)检测60例膀胱癌者、20例非膀胱癌者、20例健康志愿者尿中NMP22水平,并同时行尿脱落细胞学检查,并对结果进行比较。结果:膀胱癌者NMP22平均为35.6×10~3U/L,高于非膀胱癌者(7.8×10~3U/L)和健康志愿者(7.2×10~3U/L,P<0.05);膀胱癌复发患者(31.5×10~3U/L)高于未复发患者(8.0×10~3U/L,P<0.05);膀胱癌者NMP22的敏感性高于尿脱落细胞学,而其特异性低于尿脱落细胞学。结论:尿NMP22对膀胱移行细胞癌具有高灵敏度和无创伤性,是检测膀胱移行细胞癌的有效标志物;联合尿细胞学检查可进一步提高膀胱癌术后复发的诊断率。
Objective: To investigate the value of urinary nuclear matrix protein 22 (NMP22) combined with urinary exfoliative cytology in diagnosis of bladder transitional cell carcinoma and postoperative recurrence monitoring. Methods: Urinary levels of NMP22 in 60 cases of bladder cancer, 20 cases of non-bladder cancer and 20 healthy volunteers were detected by enzyme-linked immunosorbent assay (ELISA), and cytology examination of urinary excretion was performed at the same time, and the results were compared. Results: The average NMP22 in bladder cancer patients was 35.6 × 10 ~ 3U / L, higher than those in non-bladder cancer patients (7.8 × 10 ~ 3U / L) and healthy volunteers (7.2 × 10 ~ 3U / L, P <0.05) The patients with cancer recurrence (31.5 × 10 ~ 3U / L) were higher than those without recurrence (8.0 × 10 ~ 3U / L, P <0.05). The sensitivity of bladder cancer patients with NMP22 was higher than that of urine exfoliative cytology, In urine exfoliation cytology. Conclusion: Urinary NMP22 is a sensitive and noninvasive marker of transitional cell carcinoma of the bladder and is an effective marker for detecting transitional cell carcinoma of the bladder. Combined urinary cytology can further improve the diagnostic rate of bladder cancer recurrence.